William Radany has been named CEO of HTG, the array company said this week. He replaces Kirk Collamer, who will remain with HTG as its chief financial officer.
Radany joins HTG from Chemicon International, an immunological reagents, immunodiagnostics, and molecular biology products provider, where he served as vice president of business segment management.
Prior to Chemicon International, Radany was chief business officer at Xencor. He has also served as vice president of drug discovery programs at both Caliper Technologies and Stratagene, as well as president of Biacore.
Radany holds a BS in cell biology from Colorado State University and a PhD in biochemistry and physiology from the University of Wyoming.
ExonHit Therapeutics has hired John Jaskowiak as executive vice president of business and marketing. Jaskowiak will work out of the Paris-based company’s US subsidiary in Gaithersburg, Md.
Jaskowiak comes to ExonHit from Affymetrix, where he was senior director of marketing. His goal at ExonHit will be to “develop a partnering business model for ExonHit's genomics efforts to expand ExonHit's business in diagnostics and personalized medicines," the company said in a statement.
Gene Logic has extended until Dec. 31 the employment of Larry Tiffany as senior vice president and interim general manager of its Genomics Division. The company originally signed him up for these duties on June 30 and said he would remain employed until Aug. 31.
DeCode Genetics appointed Peter Goodfellow to its board of directors, effective immediately.
Goodfellow was until recently senior vice president for discovery research at GlaxoSmithKline. He received his PhD from Oxford University